blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3640345

EP3640345 - METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.08.2022
Database last updated on 06.07.2024
FormerThe patent has been granted
Status updated on  03.09.2021
FormerGrant of patent is intended
Status updated on  18.04.2021
FormerExamination is in progress
Status updated on  06.05.2020
FormerRequest for examination was made
Status updated on  20.03.2020
Most recent event   Tooltip12.08.2022No opposition filed within time limitpublished on 14.09.2022  [2022/37]
Applicant(s)For all designated states
Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130 / US
[2021/40]
Former [2020/17]For all designated states
Kura Oncology, Inc.
3033 Science Park Road, Suite 220
San Diego, CA 92121 / US
Inventor(s)01 / GUALBERTO, Antonio
8 Larch Road
Acton, MA Massachusetts 01720 / US
02 / SCHOLZ, Catherine Rose
8 James Millen Road
North Reading, MA Massachusetts 01864 / US
 [2020/17]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2020/17]
Application number, filing date19210527.816.08.2016
[2020/17]
Priority number, dateUS201562206194P17.08.2015         Original published format: US 201562206194 P
US201562218927P15.09.2015         Original published format: US 201562218927 P
US201562241019P13.10.2015         Original published format: US 201562241019 P
US201662310582P18.03.2016         Original published format: US 201662310582 P
US201662372662P09.08.2016         Original published format: US 201662372662 P
[2020/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3640345
Date:22.04.2020
Language:EN
[2020/17]
Type: B1 Patent specification 
No.:EP3640345
Date:06.10.2021
Language:EN
[2021/40]
Type: B9 Corrected patent specification 
No.:EP3640345
Date:24.11.2021
[2021/47]
Search report(s)(Supplementary) European search report - dispatched on:EP25.03.2020
ClassificationIPC:C12Q1/6886
[2021/18]
CPC:
A61K31/4709 (EP,IL,KR,US); C12Q1/6886 (EP,CN,IL,KR,US); A61K31/4725 (IL,KR);
A61K45/00 (CN,IL); A61K45/06 (IL,KR,US); A61P35/00 (EP,CN,IL);
A61P35/02 (EP,CN,IL); A61P35/04 (EP,CN,IL); A61P43/00 (EP,IL);
C12Q2600/106 (CN,IL,KR,US); C12Q2600/156 (EP,CN,IL,KR,US); C12Q2600/158 (CN,IL,KR,US) (-)
Former IPC [2020/17]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/17]
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON KREBSPATIENTEN MIT FARNESYL-TRANSFERASE-INHIBITOREN[2020/17]
English:METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS[2020/17]
French:MÉTHODES DE TRAITEMENT DE PATIENTS CANCÉREUX À L'AIDE D'INHIBITEURS DE FARNÉSYLTRANSFÉRASES[2020/17]
Examination procedure21.11.2019Examination requested  [2020/17]
25.03.2020Date on which the examining division has become responsible
11.05.2020Despatch of a communication from the examining division (Time limit: M04)
17.09.2020Reply to a communication from the examining division
27.10.2020Despatch of a communication from the examining division (Time limit: M04)
17.02.2021Reply to a communication from the examining division
19.04.2021Communication of intention to grant the patent
26.08.2021Fee for grant paid
26.08.2021Fee for publishing/printing paid
26.08.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP16757791.5  / EP3277842
EP18173134.0  / EP3385395
Divisional application(s)EP21200474.1  / EP3995589
Opposition(s)07.07.2022No opposition filed within time limit [2022/37]
Fees paidRenewal fee
21.11.2019Renewal fee patent year 03
21.11.2019Renewal fee patent year 04
13.08.2020Renewal fee patent year 05
13.08.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2012016021  (VERIDEX LLC [US], et al) [A] 1-15 * the whole document *;
 [AP]WO2015164862  (SLOAN KETTERING INST CANCER [US]) [AP] 1-15 * paragraphs [[0005]] - [[0012]]; figures 2A, 2B; claims 1-23 *;
 [A]  - OH S-H ET AL, "Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma", CLINICAL CANCER RESE, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20060101), vol. 12, no. 2, doi:10.1158/1078-0432.CCR-05-1725, ISSN 1078-0432, pages 653 - 661, XP008106229 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-05-1725
 [A]  - YAO R ET AL, "Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: Role of Ha-ras mutations and use of microarray analysis in identifying potential targets", CARCINOGENESIS 200607 GB, (200607), vol. 27, no. 7, ISSN 0143-3334, pages 1420 - 1431, XP002763821 [A] 1-15 * the whole document *
 [A]  - SHI YUQUAN ET AL, "Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival", PROSTATE, (20050101), vol. 62, no. 1, ISSN 0270-4137, pages 69 - 82, XP002763822 [A] 1-15 * the whole document *
 [A]  - X CHEN ET AL, "Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition", ONCOGENE, GB, (20131118), vol. 33, no. 47, doi:10.1038/onc.2013.489, ISSN 0950-9232, pages 5442 - 5449, XP055232606 [A] 1-15 * page 5447; figure 4 *

DOI:   http://dx.doi.org/10.1038/onc.2013.489
 [A]  - M H KIRSCHBAUM ET AL, "A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia", LEUKEMIA., US, (20110531), vol. 25, no. 10, doi:10.1038/leu.2011.124, ISSN 0887-6924, pages 1543 - 1547, XP055494386 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/leu.2011.124
 [A]  - JUAN JOSE PEREZ-RUIXO ET AL, "Exposure-toxicity relationships for tipifarnib in cancer patients", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., GB, (20070801), vol. 64, no. 2, doi:10.1111/j.1365-2125.2007.02883.x, ISSN 0306-5251, pages 219 - 232, XP055494402 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1365-2125.2007.02883.x
 [A]  - DELPHINE ROLLAND ET AL, "Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, (20091204), vol. 65, no. 4, ISSN 1432-0843, pages 781 - 790, XP019779242 [A] 1-15 * the whole document *
Examination   - Yoshimasa Saito ET AL, "MicroRNAs in Hepatobiliary and Pancreatic Cancers", FRONTIERS IN GENETICS, Switzerland, (20110101), vol. 2, doi:10.3389/fgene.2011.00066, ISSN 1664-8021, XP055228584

DOI:   http://dx.doi.org/10.3389/fgene.2011.00066
    - I. A. Prior ET AL, "A Comprehensive Survey of Ras Mutations in Cancer", Cancer research, (20120514), vol. 72, no. 10, doi:10.1158/0008-5472.CAN-11-2612, ISSN 0008-5472, pages 2457 - 2467, XP055117242

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-2612
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US4016043
 US4018653
 US4044126
 US4328245
 US4364923
 US4409239
 US4410545
 US4414209
 US4424279
 US4870287
 US5033252
 US5052558
 US5059595
 US5073543
 WO9208800
 US5120548
 US5210015
 US5238922
 WO9318186
 US5310652
 WO9410138
 US5322770
 US5323907
 US5354556
 US5399491
 US5409818
 US5420245
 US5437990
 US5455166
 US5468611
 US5487972
 US5491164
 US5491063
 US5504212
 US5523430
 US5532359
 US5534537
 US5561058
 US5571673
 US5578629
 US5585359
 US5591767
 US5602098
 US5639476
 US5639480
 US5641864
 US5661161
 WO9730992
 US5674533
 US5693517
 US5700806
 US5721236
 US5733566
 US5739108
 US5750567
 US5756528
 US5760395
 US5767274
 US5773455
 WO9828303
 US5777324
 US5780492
 US5804375
 US5807852
 US5843941
 US5852010
 US5856439
 US5856326
 US5859015
 US5861529
 US5869682
 US5872135
 US5874442
 US5880140
 US5889053
 US5891889
 US5891474
 US5922356
 US5936097
 US5939557
 WO9945712
 WO9945912
 US5958939
 US5965578
 US5965539
 US5968965
 US5968952
 US5972984
 US5972966
 US5972891
 US5976851
 US5980945
 US5993855
 WO0001691
 WO0012498
 WO0012499
 US6037350
 US6045830
 US6087324
 US6104028
 US6111251
 US6113943
 US6169096
 US6177432
 US6187786
 US6197350
 US6248363
 US6258538
 US6264970
 US6267981
 US6300076
 US6376461
 US6419961
 US6423966
 US6500621
 US6545020
 US6558902
 US6569385
 US6589548
 US6613358
 US6670124
 US6699500
 US6706530
 US6723564
 US6740634
 US6838467
 WO2005046459
 US6927024
 US7101663
 US7122799
 US2007048782
 US7186507
 US7189740
 WO2007041067
 US2008051379
 US7393862
 US2008213787
 US2008280289
 US7468363
 WO2009051672
 US7932036
 WO2012047985
 US8435740
 US2013267613
 US8771951
 WO2015144184
    - UHRBERG et al., Immunity, (19970000), vol. 7, pages 753 - 763
    - COLONNA et al., PNAS, (19930000), vol. 90, pages 1200 - 12004
    - MOESTA AK et al., Front Immunol., (20120000), vol. 3, page 336
    - POOT, Cell Death and Differentiation, (20140000), vol. 21, pages 359 - 368
    - LANCET et al., Blood, (20060000), vol. 2, page 2
    - YOKOTA, Anti- Cancer Agents in Medicinal Chemistry, (20120000), vol. 12, pages 163 - 171
    - HERREROS-VILLANUEVA et al., Clinica Chimica Acta, (20140000), vol. 431, no. 21, pages 1 - 220
    - "GENBANK", Database accession no. NM 033360.3
    - METZELER KH et al., Blood, (20080000), vol. 112, pages 4193 - 201
    - SHEN et al., Drug Disc. Today, (20150000), vol. 20, page 2
    - DUEZ, S. et al., Bioorg. Med. Chem., (20100000), vol. 18, pages 543 - 556
    - KOHL, N.E. et al., PNAS, (19940000), vol. 91, pages 9141 - 9145
    - LEE, H-Y. et al., Bioorg. Med. Chem. Lett., (20020000), vol. 12, pages 1599 - 1602
    - HAROUSSEAU et al., Blood, (20090000), vol. 114, pages 1166 - 1173
    - THOMAS et al., Biologies, (20070000), vol. 1, pages 415 - 424
    - APPELS et al., The Oncologist, (20050000), vol. 10, pages 565 - 578
    - LI et al., Electrophoresis, (19990000), vol. 20, pages 1258 - 1265
    - "General Concepts for PCR Primer Design", DIEFFENBACH, Carstensen, Drug Stability: Principles & Practice, Cold Spring Harbor Laboratory Press, (19950000), pages 133 - 155
    - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201
    - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507
    - SAUDEK et al., N. Engl. J. Med., (19890000), vol. 321, page 574
    - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - CHENG DT et al., JMol Diagn., (20150000), vol. 17, no. 3, pages 251 - 64
    - ZUJEWSKI J., J Clin Oncol., (20000200), vol. 18, no. 4, pages 927 - 41
    - LARA PN JR., Anticancer Drugs., (20050000), vol. 16, no. 3, pages 317 - 21
    - KIRSCHBAUM MH, Leukemia., (20111000), vol. 25, no. 10, pages 1543 - 7
    - K. STAHNKE et al., Blood, (20010000), vol. 98, pages 3066 - 3073
    - MESA, Lancet Oncol, (20060000), vol. 6, pages 279 - 286
    - RAO et al., J Clin Oncol, (20040000), vol. 22, pages 3950 - 3957
    - RAPONI et al., Clin Cancer Res., (20070000), vol. 13, pages 2254 - 60
    - KAMASANI et al., Cancer Biology & Therapy, (20070000), vol. 6, pages 1418 - 1423
    - LANCET et al., Blood (ASH, (20120000), vol. 120
    - SERIO et al., Blood (ASH Annual Meeting Abstracts, (20060000), vol. 108
    - COOK et al., Blood, (20040000), vol. 103, pages 1521 - 152
    - LEBEDEVA et al., Hum Immun., (20070000), vol. 68, no. 9, pages 789 - 96
    - GONZALEZ et al., Hum Immun., (20090000), vol. 70, no. 10, pages 858 - 63
    - YUN et al., Blood (ASH Annual Meeting Abstracts, (20050000), vol. 106
    - YUN et al., Clin Immunol., (20070000), vol. 123, no. 3, pages 272 - 280
    - LEUNG et al., J Immun., (20050000), vol. 174, pages 6540 - 6545
    - HOUTCHENS et al., Immunogenetics, (20070000), vol. 59, no. 7, pages 525 - 37
    - GOMEZ- LOZANO et al., Tissue Antigens, (20020000), vol. 59, no. 3, pages 184 - 193
    - SHILLING et al., J Immunol., (20020000), vol. 168, pages 2307 - 2315
    - COOK et al., Hum. Immunology, (20030000), vol. 64, pages 567 - 571
    - CRUM et al., Tissue Antigens, (20000000), vol. 56, pages 313 - 326
    - MIDDLETON et al., Transplant immunology, (20020000), vol. 10, pages 147 - 164
    - ROSS et al., Nature Biotech., (19980000), vol. 16, pages 1347 - 1351
    - FEI et al., Rapid Comm. Mass. Spec., (20000000), vol. 14, pages 950 - 959
    - FEI et al., NAR, (19980000), vol. 26, no. 11, pages 2827 - 2828
    - BUETOW et al., PNAS, (20010000), vol. 98, no. 21, pages 12097 - 12102
    - STORM et al., Methods in Mol. Biol., (20030000), vol. 212, pages 241 - 262
    - PARHAM, Immunology Lett., (20040000), vol. 92, pages 11 - 13
    - TIERCY et al., Blood Review, (19900000), vol. 4, pages 9 - 15
    - SAIKI et al., Proc. Natl. Acad. Sci., U.S.A., (19890000), vol. 86, pages 6230 - 6234
    - ERLICH et al., Eur. J. Immunogenet., (19910000), vol. 18, no. 1-2, pages 33 - 55
    - KAWASAKI et al., Methods Enzymol., (19930000), vol. 218, pages 369 - 381
    - OLERUPZETTERQUIST, Tissue Antigens, (19920000), vol. 39, pages 225 - 235
    - PARKERBARNES, Methods in Molecular Biology, (19990000), vol. 106, pages 247 - 283
    - HOD, Biotechniques, (19920000), vol. 13, pages 852 - 854
    - WEIS, Trends in Genetics, (19920000), vol. 8, pages 263 - 264
    - WUWALLACE, Genomics, (19880000), vol. 4, pages 560 - 569
    - WALKER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 392 - 396
    - KWOH et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 1173 - 1177
    - GUATELLI et al., Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 1874 - 1878
    - KRAMERLIZARDI, Nature, (19890000), vol. 339, pages 401 - 402
    - LOMELI et al., Clin. Chem., (19890000), vol. 35, pages 1826 - 1831
    - ABRAMSOMYERS, Current Opinion in Biotechnology, (19930000), vol. 4, pages 41 - 47
    - PLASTERER, T. N., Primerselect: Primer and probe design. Methods Mol. Biol., (19970000), vol. 70, pages 520 - 527
    - BUSTIN et al., Clin. Sci., (20050000), vol. 109, pages 365 - 379
    - HOLLAND et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 88, pages 7276 - 7280
    - KENT, W., Genome Res., (20020000), vol. 12, no. 4, pages 656 - 64
    - INNISGELFAND, Optimization of PCRs'' in: PCR Protocols, A Guide to Methods and Applications, Humana Press, (19940000), pages 365 - 386
    - WANG et al., Nature Reviews Genetics, (20090100), vol. 10, no. 1, pages 57 - 63
    - RYAN et al., BioTechniques, (20080000), vol. 45, no. 1, pages 81 - 94
    - MAHER et al., Nature, (20090100), vol. 458, no. 7234, pages 97 - 101
    - SCHENA et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, no. 2, pages 106 - 149
    - VELCULESCU, Science, (19950000), vol. 270, pages 484 - 487
    - VELCULESCU et al., Cell, (19970000), vol. 88, pages 243 - 51
    - KALLIONIEMI et al., Science, (19920000), vol. 258, pages 818 - 821
    - LIN SY et al., Am J Clin Pathol., (19930000), vol. 100, pages 686 - 689
    - GALL et al., Meth. Enzymol., (19810000), vol. 21, pages 470 - 480
    - EPSTEINSLEASE, Surg. Ann., (19850000), vol. 17, pages 125 - 65
    - MOORE, Annu. Rev. Immunol., (19910000), vol. 9, page 159
    - LIST, J Clin. Oncol., (19900000), vol. 8, page 1424
    - KAMARCH, Methods Enzymol, (19870000), vol. 151, pages 150 - 165
    - SOREIDE, J Clin Pathol, (20080000), vol. 10.1136
    - The Merck Manual, (19990000), vol. 954, pages 949 - 952
    - JEMAL A et al., CA Cancer J Clin, (20070000), vol. 57, no. 1, pages 43 - 66
    - CLARKE C A et al., Cancer, (20020000), vol. 94, no. 7, pages 2015 - 2023
    - D. KIM et al., "ASCO Annual Meeting Proceedings", Journal of Clinical Oncology, (20070620), vol. 25, no. 18S, page 8082
    - BOWEN et al., Blood, (20050000), vol. 106, pages 2113 - 2119
    - NGO V.N. et al., Nature, (20110000), vol. 470, pages 115 - 9
    - Cancer: Principles & Practice of Oncology, (19890000), pages 1843 - 1847
    - BENNETT J. M. et al., Ann. Intern. Med., (19851010), vol. 3, no. 4, pages 620 - 5
    - BESA E. C., Med. Clin. North Am., (19920507), vol. 6, no. 3, pages 599 - 617
    - DEXTER, J. Cell Sci., (19870000), vol. 88, page 1
    - STOLER, Clin. Lab. Med., (19900000), vol. 12, pages 215 - 36
    - CHANG et al., Clinical Biochemistry, (20100000), vol. 43, pages 296 - 301
    - PLoS One, (20130821), vol. 8, no. 8, page e72239
    - KURZROCK et al., Blood, (20030000), vol. 102, no. 13, pages 4527 - 2774
    - NISHIKAWA et al., Clin Chim Acta., (20020000), vol. 318, pages 107 - 112
    - O'LEARY JJ et al., J Clin Pathol., (19980000), vol. 51, pages 576 - 582
    - D. KIM et al., "Journal of Clinical Oncology", ASCO Annual Meeting Proceedings, (20070000), vol. 25, no. 18S, page 8082
    - LIANG C et al., Cancer Res., (20120000), vol. 72, pages 5004 - 5013
    - HAROUSSEAU et al., Blood, (20070000), vol. 109, pages 1387 - 1394
    - RAPONI et al., Clin. Cancer Res., (20070000), vol. 13, pages 2254 - 2260
    - MA et al., Cancer Cell, (20040000), vol. 5, pages 607 - 616
 US20020380842
 WO2008US11671
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.